Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
September 03, 2024 16:05 ET
|
Metagenomi, Inc.
Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and...
Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference
August 29, 2024 19:32 ET
|
Metagenomi, Inc.
AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that...
Metagenomi to Participate in Upcoming Investor Conferences
August 28, 2024 18:10 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
August 14, 2024 08:05 ET
|
Metagenomi, Inc.
Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 2024 All Wave 1 Ionis collaboration...
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
May 29, 2024 16:00 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
May 14, 2024 16:05 ET
|
Metagenomi, Inc.
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024;...
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
May 01, 2024 16:00 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi to Present at Upcoming Scientific Meetings
April 08, 2024 08:00 ET
|
Metagenomi, Inc.
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8...
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
March 27, 2024 09:16 ET
|
Metagenomi, Inc.
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of...
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
February 29, 2024 16:30 ET
|
Metagenomi Technologies, LLC
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for...